Furthermore, treatment with SGLT2 inhibitors leads invariably to a decrease in serum ferritin and transferrin saturation in laboratory findings that meet the typical current diagnostic criteria for an ensuing iron deficiency (Figure 2). This evidence concerns the gene SLC5A2 and Iron deficiency anemia.